Securities Code: 688098 Securities Abbreviations: Shenlian Biological Announcement No.: 2022-040

Shenlian Biomedical (Shanghai) Co., Ltd.

A suggestive announcement on changes in shareholders' equity.

The board of directors, all directors and relevant shareholders of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and completeness of its contents.

Important note:

This change in equity is a shareholder reduction and does not touch the tender offer.

After this change in equity, the company's shareholder, United Biomedical Corporation (UNITED

BIOMEDICAL,INC., hereinafter referred to as "UBI") holds 47,680,298 shares of the company, accounting for 11.61% of the company's total share capital.

This change in equity is a reduction in the holding of more than 5% of the non-first largest shareholder, which will not lead to changes in the company's controlling shareholders and actual controllers.

On December 20, 2022, the Company received a "Short Form Report on Changes in Equity" from shareholder UBI.

UBI from November 30, 202020 to December 19, 2022 through centralized bidding and block trading parties

The cumulative reduction of 20,550,152 shares of the company, the cumulative reduction of shares to 5.00% of the total number of shares of the company. The relevant changes in equity are hereby announced under:

1. the basic information of this equity change.

Basic Information of (I) Information Disclosure Obligor

Enterprise name UNITED BIOMEDICAL,INC.

Enterprise Type Overseas Legal Person

Chairman Joop Sistermans

Registered address 4303 Lancaster, Wilmington, County of New Castle,DE

19808,USA

The scope of business research, development and production includes immune drugs for chronic and infectious diseases,

Biological products, treatment programs, etc.

Name of major shareholder or CYW FLP,LTD holding 22.76%;

Name ML FLP,LTD holding 20.43%;

HU,N. holding 11.23%;

BLACKFOOT HEALTHCARE VENTURES L holds 7.73%;

BAXALTA INCROPORATED holds 6.69%.

(II) the basic information of this equity change.

During the period from November 30, 2020 to December 19, 2022, UBI conducted centralized bidding and bulk delivery.

Yi reduced 20,550,152 shares of the company in total, accounting for 5.00 percent of the company's total share capital, of which 11,977,352 shares of the company were reduced through centralized bidding, accounting for 2.92 percent of the company's total share capital, and 8,572,800 shares were reduced through block trading, accounting for 2.09 percent of the company's total share capital. The details of this change in equity are as follows:

Name of shareholder Reduction Reduction Time Reduction Quantity Reduction Price Zone Change Ratio

Examples of (yuan) between methods (shares)

2022/11/30- 6,092,000 11.92-17.82 1.48%

2021/5/26

Concentrate 2022/1/19- 4,106,440 9.79-11.38 1.00%

Bidding 2022/3/3

UNITED 2022/6/28-

BIOMEDICAL, 2022/12/19 1,778,912 8.80-9.55 0.43%

INC. 2022/1/20 5,567,400 8.97 1.36%

Bulk 2022/1/24 2,645,400 8.80 0.64%

Transaction 2022/12/19 360,000 8.80 0.09%

Total 20,550,152 8.80-17.82 5.00%

Note: If the total number does not match the sum of the itemized values, it is due to rounding, and the above shareholding ratio is calculated according to the company's total share capital of 410,644,000 shares.

(III) before and after the change in equity, the information disclosure obligor holds the company's shares.

Prior to the change in equity, UBI held a total of 68,230,450 shares of the listed company, accounting for the total share capital of the company.

16.62%. After the completion of this equity change, UBI holds 47,680,298 shares of the company, which reduces the proportion of the company's total share capital from 16.62% to 11.61%.

Shares held before this change Shares held after this change

Name of shareholder Nature of shares Number of shares Number of total shares Number of total shares Number of total shares

(share) capital ratio (share) capital ratio

UNITED Unlimited Sale Flow

BIOMEDICAL,I-share 68,230,450 16.62% 47,680,298 11.61%

NC.

Follow-up matters related to 2.

(I) this change in equity is a shareholder reduction and does not touch the tender offer.

(II) this change in equity will not lead to changes in the company's controlling shareholders and actual controllers, and will not affect the company's governance structure and continuing operations.

(III) the above-mentioned shareholders have prepared a report on changes in equity. For details, please refer to the "Report on Changes in Equity of Shenlian Biomedical (Shanghai) Co., Ltd." disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same day.

(IV) this equity change, UBI is still in the reduction period. During the implementation of the reduction plan, the relevant shareholders will strictly abide by the corresponding regulations and fulfill their information disclosure obligations in a timely manner. Investors are advised to pay attention to investment risks.

It is hereby announced.

Board of Directors of Shenlian Biomedical (Shanghai) Co., Ltd.

21 December 2022